
Roman Rouzier

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6304008/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Quality of Life in an e-Cohort of Women Treated by Endocrine Therapy for Early Breast Cancer. Clinical Breast Cancer, 2022, 22, e352-e361.	1.1	5
2	Impact of catch-up human papillomavirus vaccination on cervical conization rate in a real-life population in France. PLoS ONE, 2022, 17, e0264821.	1.1	1
3	Variation over time of the factors influencing return to work and work capacities after a diagnosis of breast cancer: a study on the behalf of the Seintinelles research network. Supportive Care in Cancer, 2022, 30, 5991-5999.	1.0	5
4	Human papilloma virus integration sites and genomic signatures in head and neck squamous cell carcinoma. Molecular Oncology, 2022, 16, 3001-3016.	2.1	7
5	Absenteeism and indirect costs during the year following the diagnosis of an operable breast cancer: A prospective multicentric cohort study. Journal of Gynecology Obstetrics and Human Reproduction, 2021, 50, 101871.	0.6	6
6	Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site. British Journal of Cancer, 2021, 124, 777-785.	2.9	44
7	Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592098765.	1.4	13
8	Total metabolic tumor volume and spleen metabolism on baseline [18F]-FDG PET/CT as independent prognostic biomarkers of recurrence in resected breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3560-3570.	3.3	14
9	Correlation of ultrasound, cytological, and histological features of 110 benign Blâ€RADS categories 4C and 5 nonpalpable breast lesions. The Institut Curie's experience. Cancer Cytopathology, 2021, 129, 479-488.	1.4	4
10	Adherence to French and ESGO Quality Indicators in Ovarian Cancer Surgery: An Ad-Hoc Analysis from the Prospective Multicentric CURSOC Study. Cancers, 2021, 13, 1593.	1.7	5
11	18F-FDG PET/CT in Relapsed Endometrial Cancer Treated with Preoperative PD-1 Inhibitor Dostarlimab. Diagnostics, 2021, 11, 1353.	1.3	0
12	Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database. Gynecologic Oncology, 2021, 163, 64-71.	0.6	3
13	Human papillomavirus (HPV) vaccine coverage rates (VCRs) in France: A French claims data study. Vaccine, 2021, 39, 5129-5137.	1.7	3
14	Laparoscopic management of advanced epithelial ovarian cancer after neoadjuvant chemotherapy: a phase II prospective multicenter non-randomized trial (the CILOVE study). International Journal of Gynecological Cancer, 2021, 31, ijgc-2021-002888.	1.2	4
15	A subset of activated fibroblasts is associated with distant relapse in early luminal breast cancer. Breast Cancer Research, 2020, 22, 76.	2.2	41
16	Genetic markers and phosphoprotein forms of beta-catenin pβ-Cat552 and pβ-Cat675 are prognostic biomarkers of cervical cancer. EBioMedicine, 2020, 61, 103049.	2.7	10
17	Associated Lichen Sclerosis Increases the Risk of Lymph Node Metastases of Vulvar Cancer. Journal of Clinical Medicine, 2020, 9, 250.	1.0	1
18	Clinical Interest of Combining Transcriptomic and Genomic Signatures in High-Grade Serous Ovarian Cancer. Frontiers in Genetics, 2020, 11, 219.	1.1	21

#	Article	IF	CITATIONS
19	Direct medical and non-medical costs of a one-year care pathway for early operable breast cancer: Results of a French multicenter prospective study. PLoS ONE, 2019, 14, e0210917.	1.1	11
20	Impact of time to local recurrence on the occurrence of metastasis in breast cancer patients treated with neoadjuvant chemotherapy: A random forest survival approach. PLoS ONE, 2019, 14, e0208807.	1.1	10
21	HPV DNA integration site as proof of the origin of ovarian metastasis from endocervical adenocarcinoma: three case reports. BMC Cancer, 2019, 19, 375.	1.1	17
22	Threatened preterm birth: Validation of a nomogram to predict the individual risk of very preterm delivery in a secondary care center. Journal of Gynecology Obstetrics and Human Reproduction, 2019, 48, 501-507.	0.6	3
23	Clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome. EBioMedicine, 2019, 43, 253-260.	2.7	37
24	Mechanistic Signatures of Human Papillomavirus Insertions in Anal Squamous Cell Carcinomas. Cancers, 2019, 11, 1846.	1.7	19
25	Lymph node positivity in different early breast carcinoma phenotypes: a predictive model. BMC Cancer, 2019, 19, 45.	1.1	20
26	Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study. Breast Cancer Research and Treatment, 2019, 173, 343-352.	1.1	163
27	Isolated ipsilateral local recurrence of breast cancer: predictive factors and prognostic impact. Breast Cancer Research and Treatment, 2019, 173, 111-122.	1.1	16
28	The role of neoadjuvant chemotherapy in ovarian cancer. Expert Review of Anticancer Therapy, 2018, 18, 555-566.	1.1	34
29	Benefit of the addition of hormone therapy to neoadjuvant anthracycline-based chemotherapy for breast cancer: comparison of predicted and observed pCR. Journal of Cancer Research and Clinical Oncology, 2018, 144, 601-606.	1.2	3
30	A multidisciplinary approach to oncology trials: Study conduct of the ANTHALYA trial. Contemporary Clinical Trials, 2018, 65, 151-156.	0.8	0
31	Relevance of a molecular tumour board (MTB) for patients' enrolment in clinical trials: experience of the Institut Curie. ESMO Open, 2018, 3, e000339.	2.0	37
32	Risk of Serous Endometrial Carcinoma in Women With Pathogenic BRCA1/2 Variant After Risk-Reducing Salpingo-Oophorectomy. Journal of the National Cancer Institute, 2018, 110, 213-215.	3.0	33
33	Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast. Modern Pathology, 2018, 31, 68-82.	2.9	58
34	Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 ASO4-adjuvanted vaccine and 4vHPV vaccine administered according to two- or three-dose schedules in girls aged 9–14â€years: Results to month 36 from a randomized trial. Vaccine, 2018, 36, 98-106.	1.7	21
35	High rate of <i><scp>PIK</scp>3<scp>CA</scp></i> mutations but no <i><scp>TP</scp>53</i> mutations in lowâ€grade adenosquamous carcinoma of the breast. Histopathology, 2018, 73, 273-283.	1.6	33
36	Multidimensional impact of breast cancer screening: Results of the multicenter prospective optisoins01 study. PLoS ONE, 2018, 13, e0202385.	1.1	3

#	Article	IF	CITATIONS
37	Medullary Breast Carcinoma, a Triple-Negative Breast Cancer Associated with BCLG Overexpression. American Journal of Pathology, 2018, 188, 2378-2391.	1.9	12
38	Determinants of return at work of breast cancer patients: results from the OPTISOINS01 French prospective study. BMJ Open, 2018, 8, e020276.	0.8	35
39	Value of Diaphragmatic Surgery During Interval Debulking Surgery. Anticancer Research, 2018, 38, 411-416.	0.5	1
40	Denaturing fixatives are compatible with the NanoString nCounter® platform and the Prosigna® assay. New Biotechnology, 2017, 36, 37-41.	2.4	1
41	Colpoplasty by laparoscopic modified Davydov's procedure. Gynecologic Oncology, 2017, 144, 647-648.	0.6	0
42	Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study. Breast Cancer Research and Treatment, 2017, 162, 307-316.	1.1	16
43	European Society of Gynaecological Oncology Guidelines for the Management of Patients With Vulvar Cancer. International Journal of Gynecological Cancer, 2017, 27, 832-837.	1.2	149
44	Therapeutic escalation – De-escalation: Data from 15.508 early breast cancer treated with upfront surgery and sentinel lymph node biopsy (SLNB). Breast, 2017, 34, 24-33.	0.9	7
45	The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2â^') breast cancer: When might multigene assays be of value?. Breast, 2017, 33, 191-199.	0.9	4
46	Preoperative clinical pathway of breast cancer patients: determinants of compliance with EUSOMA quality indicators. British Journal of Cancer, 2017, 116, 1394-1401.	2.9	17
47	Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial. European Journal of Cancer, 2017, 70, 133-142.	1.3	86
48	Diagnostic Performance of Ultrasound-Guided Fine-Needle Aspiration of Nonpalpable Breast Lesions in a Multidisciplinary Setting. American Journal of Clinical Pathology, 2017, 147, 571-579.	0.4	27
49	Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer. Annals of Oncology, 2017, 28, 2233-2240.	0.6	75
50	Multicenter prospective evaluation of the reliability of the combined use of two models to predict non-sentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: the MSKCC nomogram and the Tenon score. Results of the NOTEGS study. British Journal of Cancer, 2017, 116, 1135-1140.	2.9	8
51	Physician-to-physician communication in breast cancer care coordination. Bulletin Du Cancer, 2017, 104, 690-693.	0.6	Ο
52	Faisabilité et tolérance de Sienna+ ® pour la détection du ganglion sentinelleÂ: étude pilote unicentrique sur 30Âcas consécutifs. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2017, 21, 305-306.	0.6	1
53	Predictive factors of pathologic complete response of HER2-positive breast cancer after preoperative chemotherapy with trastuzumab: development of a specific predictor and study of its utilities using decision curve analysis. Breast Cancer Research and Treatment, 2017, 161, 73-81.	1.1	7
54	Medico-economic impact of MSKCC non-sentinel node prediction nomogram for ER-positive HER2-negative breast cancers. PLoS ONE, 2017, 12, e0169962.	1.1	4

#	Article	IF	CITATIONS
55	Determinants of geographic inequalities in HPV vaccination in the most populated region of France. PLoS ONE, 2017, 12, e0172906.	1.1	18
56	Evaluation and Selection of Quality Indicators for the Management of Endometrial Cancer. International Journal of Gynecological Cancer, 2017, 27, 979-986.	1.2	5
57	Clinical validation of a model predicting the risk of preterm delivery. PLoS ONE, 2017, 12, e0171801.	1.1	9
58	Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna® Test in the management of early-stage breast cancers. PLoS ONE, 2017, 12, e0185753.	1.1	15
59	Tumoral heterogeneity of breast cancer. Annales De Biologie Clinique, 2016, 74, 653-660.	0.2	53
60	Choroidal melanoma and pregnancy. Acta Ophthalmologica, 2016, 94, e652-e660.	0.6	9
61	Survival impact and predictive factors of axillary recurrence after sentinel biopsy. European Journal of Cancer, 2016, 58, 73-82.	1.3	26
62	Axillary lymph node micrometastases decrease triple-negative early breast cancer survival. British Journal of Cancer, 2016, 115, 1024-1031.	2.9	23
63	Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptor–positive, human epidermal growth factor receptor 2–negative early-stage breast cancer. European Journal of Cancer, 2016, 66, 104-113.	1.3	59
64	Response to the letter "More data along with further definitions are required―by Sahin etÂal Breast, 2016, 30, 230-233.	0.9	0
65	Breast cancer in young women: Pathologic features and molecular phenotype. Breast, 2016, 29, 109-116.	0.9	30
66	Serum CA125 and HE4 levels as predictors for optimal interval surgery and platinum sensitivity after neoadjuvant platinum-based chemotherapy in patients with advanced epithelial ovarian cancer. Journal of Ovarian Research, 2016, 9, 61.	1.3	23
67	Enabling Equal Access to Molecular Diagnostics: What Are the Implications for Policy and Health Technology Assessment?. Public Health Genomics, 2016, 19, 144-152.	0.6	9
68	Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort. British Journal of Cancer, 2016, 114, 44-52.	2.9	40
69	Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials. Journal of the National Cancer Institute, 2016, 108, djv362.	3.0	71
70	Association with pregnancy increases the risk of local recurrence but does not impact overall survival in breast cancer: A case–control study of 87 cases. Breast, 2016, 30, 222-227.	0.9	26
71	Estrogen-Receptor, Progesterone-Receptor and HER2 Status Determination in Invasive Breast Cancer. Concordance between Immuno-Histochemistry and MapQuantâ,,¢ Microarray Based Assay. PLoS ONE, 2016, 11, e0146474.	1.1	34
72	Low Concordance between Gene Expression Signatures in ER Positive HER2 Negative Breast Carcinoma Could Impair Their Clinical Application. PLoS ONE, 2016, 11, e0148957.	1.1	9

#	Article	IF	CITATIONS
73	Evaluation of the Effects of Pasireotide LAR Administration on Lymphocele Prevention after Axillary Node Dissection for Breast Cancer: Results of a Randomized Non-Comparative Phase 2 Study. PLoS ONE, 2016, 11, e0156096.	1.1	4
74	Prognostic Impact of Time to Ipsilateral Breast Tumor Recurrence after Breast Conserving Surgery. PLoS ONE, 2016, 11, e0159888.	1.1	15
75	<i>ERBB2</i> mutations associated with solid variant of high-grade invasive lobular breast carcinomas. Oncotarget, 2016, 7, 73337-73346.	0.8	34
76	Impact of Neoadjuvant Chemotherapy on the Rate of Bowel Resection in Advanced Epithelial Ovarian Cancer. Anticancer Research, 2016, 36, 4865-4872.	0.5	14
77	Dynamic Analysis of CA125 Decline During Neoadjuvant Chemotherapy in Patients with Epithelial Ovarian Cancer as a Predictor for Platinum Sensitivity. Anticancer Research, 2016, 36, 1865-71.	0.5	10
78	Sexual well-being in patients with vulvar disease: results from a preliminary prospective matched case–control study. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2015, 194, 106-110.	0.5	8
79	Age impact on human papillomavirus vaccination in France in 2014: A study from the National Health Insurance Database. Bulletin Du Cancer, 2015, 102, 892-897.	0.6	4
80	From prospective biobanking to precision medicine: BIO-RAIDs – an EU study protocol in cervical cancer. BMC Cancer, 2015, 15, 842.	1.1	16
81	Computing Molecular Signatures as Optima of a Bi-Objective Function: Method and Application to Prediction in Oncogenomics. Cancer Informatics, 2015, 14, CIN.S21111.	0.9	6
82	Non-Invasive Tools for the Diagnosis of Potentially Life-Threatening Gynaecological Emergencies: A Systematic Review. PLoS ONE, 2015, 10, e0114189.	1.1	13
83	The patient-breast cancer care pathway: how could it be optimized?. BMC Cancer, 2015, 15, 394.	1.1	19
84	Outcome of oncoplastic breast-conserving surgery following bracketing wire localization for large breast cancer. Breast, 2015, 24, 370-375.	0.9	8
85	Rates of Neoadjuvant Chemotherapy and Oncoplastic Surgery for Breast Cancer Surgery: A French National Survey. Annals of Surgical Oncology, 2015, 22, 3504-3511.	0.7	42
86	Direct Comparison of Logistic Regression and Recursive Partitioning to Predict Lymph Node Metastasis in Endometrial Cancer. International Journal of Gynecological Cancer, 2015, 25, 1037-1043.	1.2	8
87	Predictive markers of chemoresistance in advanced stages epithelial ovarian carcinoma. Gynecologic Oncology, 2015, 136, 112-120.	0.6	45
88	Sentinel node biopsy for the management of early stage endometrial cancer: Long-term results of the SENTI-ENDO study. Gynecologic Oncology, 2015, 136, 54-59.	0.6	128
89	Are we able to predict survival in ER-positive HER2-negative breast cancer? A comparison of web-based models. British Journal of Cancer, 2015, 112, 912-917.	2.9	13
90	Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH Study. Oncologist, 2015, 20, 873-879.	1.9	43

#	Article	IF	CITATIONS
91	Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9–14Âyears: Results to month 12 from a randomized trial. Human Vaccines and Immunotherapeutics, 2015, 11, 1689-1702.	1.4	43
92	Genomic profile of breast cancer. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 393-394.	0.7	1
93	Staging for endometrial cancer: The controversy around lymphadenectomy – Can this be resolved?. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2015, 29, 845-857.	1.4	30
94	Clinical nomogram to predict bone-only metastasis in patients with early breast carcinoma. British Journal of Cancer, 2015, 113, 1003-1009.	2.9	28
95	<i>CCR</i> 20th Anniversary Commentary: Divide and Conquer—Breast Cancer Subtypes and Response to Therapy. Clinical Cancer Research, 2015, 21, 3575-3577.	3.2	5
96	Time-varying effect and long-term survival analysis in breast cancer patients treated with neoadjuvant chemotherapy. British Journal of Cancer, 2015, 113, 30-36.	2.9	25
97	Reexcision for positive margins in breast cancer: A predictive score of residual disease. Surgical Oncology, 2015, 24, 129-135.	0.8	9
98	Prognostic impact of discrepant Ki67 and mitotic index on hormone receptor-positive, HER2-negative breast carcinoma. British Journal of Cancer, 2015, 113, 996-1002.	2.9	21
99	Contribution of Lymphoscintigraphy for Sentinel Lymph Node Biopsy in Women with Early Stage Endometrial Cancer: Results of the SENTI-ENDO Study. Annals of Surgical Oncology, 2015, 22, 1980-1986.	0.7	25
100	Impact of Adjuvant Chemotherapy on Breast Cancer Survival: A Real-World Population. PLoS ONE, 2015, 10, e0132853.	1.1	44
101	Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy. PLoS ONE, 2015, 10, e0144359.	1.1	27
102	Pathological Characteristics of Both Tumors in Bifocal and Bicentric Breast Cancer. Anticancer Research, 2015, 35, 5111-6.	0.5	4
103	Predictive and Prognostic Value of the TauProtein in Breast Cancer. Anticancer Research, 2015, 35, 5179-84.	0.5	22
104	Histological grade concordance between diagnostic core biopsy and corresponding surgical specimen in HR-positive/HER2-negative breast carcinoma. British Journal of Cancer, 2014, 110, 2195-2200.	2.9	19
105	Value of ultrasonography and magnetic resonance imaging for the characterization of uterine mesenchymal tumors. Acta Obstetricia Et Gynecologica Scandinavica, 2014, 93, 261-268.	1.3	43
106	CA125 kinetic parameters predict optimal cytoreduction in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy. Gynecologic Oncology, 2014, 135, 542-546.	0.6	55
107	Polarity gene alterations in pure invasive micropapillary carcinomas of the breast. Breast Cancer Research, 2014, 16, R46.	2.2	40
108	Secondary Complete Cytoreduction in Recurrent Ovarian Cancer: Benefit of Optimal Patient Selection Using Scoring System. International Journal of Gynecological Cancer, 2014, 24, 238-246.	1.2	20

#	Article	IF	CITATIONS
109	Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma: systematic review and meta-analysis. Fertility and Sterility, 2014, 101, 785-794.e3.	0.5	151
110	Evaluation of a method of predicting lymph node metastasis in endometrial cancer based on five pre-operative characteristics. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2014, 172, 115-119.	0.5	18
111	Psychometric properties of the French Female Sexual Function Index (FSFI). Quality of Life Research, 2014, 23, 2079-2087.	1.5	44
112	Survival Impact of Lymphadenectomy Stratified by Nodal Metastatic Probability in Endometrial Cancer. Annals of Surgical Oncology, 2014, 21, 2376-2382.	0.7	11
113	A suggested modification to FIGO stage I endometrial cancer. Gynecologic Oncology, 2014, 133, 192-196.	0.6	30
114	A single-institution study of 117 pregnancy-associated breast cancers (PABC): Presentation, imaging, clinicopathological data and outcome. Diagnostic and Interventional Imaging, 2014, 95, 435-441.	1.8	54
115	Pregnancy stimulates tumor angiogenesis in breast carcinoma. Anticancer Research, 2014, 34, 125-31.	0.5	8
116	Expression of somatostatin type-2 and -4 receptor and correlation with histological type in breast cancer. Anticancer Research, 2014, 34, 3997-4003.	0.5	16
117	How to differentiate benign from malignant myometrial tumours using MR imaging. European Radiology, 2013, 23, 2306-2314.	2.3	143
118	Multigene assays and molecular markers in breast cancer: systematic review of health economic analyses. Breast Cancer Research and Treatment, 2013, 139, 621-637.	1.1	87
119	Simultaneous early ovarian and endometrial cancer treated conservatively with spontaneous pregnancy. Journal of Ovarian Research, 2013, 6, 59.	1.3	4
120	Sexual and functional results after creation of a neovagina in women with Mayer–Rokitansky–Küster–Hauser syndrome: a comparison of nonsurgical and surgical procedures. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2013, 169, 317-320.	0.5	26
121	Impact of lymphovascular space invasion on a nomogram for predicting lymph node metastasis in endometrial cancer. Gynecologic Oncology, 2013, 129, 292-297.	0.6	40
122	Accuracy of diagnosis on CT scan of Surgicel® Fibrillar: results of a prospective blind reading study. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2013, 169, 397-401.	0.5	17
123	Germline <i>RAD51C</i> mutations in ovarian cancer susceptibility. Clinical Genetics, 2013, 83, 332-336.	1.0	46
124	Reply. American Journal of Obstetrics and Gynecology, 2013, 208, e17.	0.7	0
125	Adnexal Masses: Development and Preliminary Validation of an MR Imaging Scoring System. Radiology, 2013, 267, 432-443.	3.6	176
126	Prediction of axillary lymph node status in male breast carcinoma. Annals of Oncology, 2013, 24, 370-376.	0.6	18

#	Article	IF	CITATIONS
127	Skin Lesions after Prophylactic Mastectomy and Immediate Reconstruction. Plastic and Reconstructive Surgery - Global Open, 2013, 1, e82.	0.3	1
128	Kaposi's Sarcoma and Pregnancy: Case Report and Literature Review. Dermatology, 2013, 226, 311-314.	0.9	10
129	Accuracy of a nomogram for prediction of lymph-node metastasis detected with conventional histopathology and ultrastaging in endometrial cancer. British Journal of Cancer, 2013, 108, 1267-1272.	2.9	22
130	An external validation study of nomograms designed to predict isolated loco-regional and distant endometrial cancer recurrences: how applicable are they?. British Journal of Cancer, 2013, 109, 1498-1503.	2.9	9
131	Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas. British Journal of Cancer, 2013, 108, 285-291.	2.9	70
132	Genomic Instability: A Stronger Prognostic Marker Than Proliferation for Early Stage Luminal Breast Carcinomas. PLoS ONE, 2013, 8, e76496.	1.1	16
133	The role of completion surgery after concurrent radiochemotherapy in locally advanced stages IB2-IIB cervical cancer. Anticancer Research, 2013, 33, 1661-6.	0.5	21
134	Correlation of immunohistopathological expression of somatostatin receptor-2 in breast cancer and tumor detection with 68Ga-DOTATOC and 18F-FDG PET imaging in an animal model. Anticancer Research, 2013, 33, 3015-9.	0.5	12
135	Contribution of pelvic and para-aortic lymphadenectomy with sentinel node biopsy in patients with IB2–IIB cervical cancer. British Journal of Cancer, 2012, 106, 39-44.	2.9	17
136	Can the centrosome be a marker for DNA ploidy in breast cancer?. Journal of Cytology, 2012, 29, 111.	0.2	2
137	Antibacterial-Coated Suture in Reducing Surgical Site Infection in Breast Surgery: A Prospective Study. International Journal of Breast Cancer, 2012, 2012, 1-8.	0.6	18
138	Eutopic endometrium and peritoneal, ovarian and colorectal endometriotic tissues express a different profile of Nectin-1, -3, -4 and nectin-like molecule 2. Human Reproduction, 2012, 27, 3179-3186.	0.4	14
139	Prognostic Value of the 2009 FIGO Staging for Endometrial Cancer: An Illustration of the E3N Cohort. International Journal of Gynecological Cancer, 2012, 22, 447-451.	1.2	7
140	Trends in Treatment and Survival of Late-Stage Squamous Cell Vulvar Carcinomas. International Journal of Gynecological Cancer, 2012, 22, 854-859.	1.2	26
141	Comparison of Morbidity and Survival Between Primary and Interval Cytoreductive Surgery in Patients After Modified Posterior Pelvic Exenteration for Advanced Ovarian Cancer. International Journal of Gynecological Cancer, 2012, 22, 1349-1354.	1.2	17
142	Expression of MMP-2, â^'7, â^'9, MT1-MMP and TIMP-1 and â^'2 has no prognostic relevance in patients with advanced epithelial ovarian cancer. Oncology Reports, 2012, 27, 1049-1057.	1.2	39
143	Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer. Breast Cancer Research and Treatment, 2012, 135, 619-627.	1.1	33
144	Preoperative systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus Conference. Breast Cancer Research and Treatment, 2012, 136, 919-926.	1.1	5

Roman Rouzier

#	Article	IF	CITATIONS
145	Safety of uterine and/or ovarian preservation in young women with grade 1 intramucous endometrial adenocarcinoma: a comparison of survival according to the extent of surgery. Fertility and Sterility, 2012, 98, 1229-1235.	0.5	50
146	Evaluation of the costs and resource use associated with adjuvant chemotherapy for breast cancer in France. Journal of Medical Economics, 2012, 15, 1167-1175.	1.0	13
147	Comparison of Diagnostic Accuracy of Frozen Section with Imprint Cytology for Intraoperative Examination of Sentinel Lymph Node in Early-Stage Endometrial Cancer: Results of Senti-Endo Study. Annals of Surgical Oncology, 2012, 19, 3515-3521.	0.7	38
148	Predictive factors for complete excision and underestimation of one-pass en bloc excision of non-palpable breast lesions with the Intact® breast lesion excision system. European Journal of Radiology, 2012, 81, 719-724.	1.2	42
149	A nomogram for predicting lymph node metastasis of presumed stage I and II endometrial cancer. American Journal of Obstetrics and Gynecology, 2012, 207, 197.e1-197.e8.	0.7	49
150	<scp>HLAâ€G</scp> 1 and <scp>HLAâ€G</scp> 5 active dimers are present in malignant cells and effusions: The influence of the tumor microenvironment. European Journal of Immunology, 2012, 42, 1599-1608.	1.6	37
151	Anorectal symptoms before and after laparoscopic sacrocolpoperineopexy for pelvic organ prolapse. International Urogynecology Journal, 2012, 23, 779-783.	0.7	13
152	Quantitative dynamic contrast-enhanced MR imaging analysis of complex adnexal masses: a preliminary study. European Radiology, 2012, 22, 738-745.	2.3	82
153	Comparison of two nomograms to predict pathologic complete responses to neoadjuvant chemotherapy for breast cancer: evidence that HER2-positive tumors need specific predictors. Breast Cancer Research and Treatment, 2012, 132, 601-607.	1.1	16
154	The survival impact of systematic lymphadenectomy in endometrial cancer with the use of propensity score matching analysis. American Journal of Obstetrics and Gynecology, 2012, 206, 500.e1-500.e11.	0.7	23
155	Pregnancy-associated breast cancers: Do they differ from other breast cancers in young women?. Breast, 2012, 21, 550-555.	0.9	59
156	Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer. Annals of Surgical Oncology, 2012, 19, 1508-1516.	0.7	401
157	Effects of pelvic organ prolapse repair on urinary symptoms: A comparative study between the laparoscopic and vaginal approach. Neurourology and Urodynamics, 2012, 31, 126-131.	0.8	17
158	Four-year functional results of the suburethral sling procedure for stress urinary incontinence: a French prospective randomized multicentre study comparing the retropubic and transobturator routes. World Journal of Urology, 2012, 30, 117-122.	1.2	21
159	Prospective study of the impact of using the 21-gene recurrence score assay on clinical decision making in women with estrogen receptor-positive, HER2-negative, early-stage breast cancer in France Journal of Clinical Oncology, 2012, 30, 568-568.	0.8	9
160	Non-Sentinel Lymph Node Metastasis Prediction in Breast Cancer with Metastatic Sentinel Lymph Node: Impact of Molecular Subtypes Classification. PLoS ONE, 2012, 7, e47390.	1.1	18
161	Facteurs de décision en chirurgie. , 2012, , 57-71.		0
162	Impact of immunohistochemical analysis of sentinel lymph node biopsy on breast cancer management. Anticancer Research, 2012, 32, 3403-9.	0.5	3

#	Article	IF	CITATIONS
163	Preoperative Evaluation of Posterior Deep-Infiltrating Endometriosis Demonstrates a Relationship with Urinary Dysfunction and Parametrial Involvement. Journal of Minimally Invasive Gynecology, 2011, 18, 36-42.	0.3	38
164	Laparoscopic pelvic lymph node dissection. Journal of Visceral Surgery, 2011, 148, e111-e116.	0.4	1
165	Laparoscopic lumbo-aortic lymph node dissection. Journal of Visceral Surgery, 2011, 148, e273-e278.	0.4	0
166	Fertility after colorectal resection for endometriosis: results of a prospective study comparing laparoscopy with open surgery. Fertility and Sterility, 2011, 95, 1903-1908.	0.5	75
167	Experience with TachoSil in obstetric and gynecologic surgery. International Journal of Gynecology and Obstetrics, 2011, 113, 112-115.	1.0	13
168	Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO). Lancet Oncology, The, 2011, 12, 469-476.	5.1	457
169	Rectovaginal Endometriosis. Annals of Surgery, 2011, 254, 540-541.	2.1	0
170	Comparative Performance of the 2009 International Federation of Gynecology and Obstetrics' Staging System for Uterine Corpus Cancer. Obstetrics and Gynecology, 2011, 117, 1225-1226.	1.2	6
171	Anaphylactic response to blue dye during sentinel lymph node biopsy. Surgical Oncology, 2011, 20, e55-e59.	0.8	128
172	Independent external validation of radiotherapy and its impact on the accuracy of a nomogram for predicting survival of women with endometrial cancer. Gynecologic Oncology, 2011, 123, 214-220.	0.6	15
173	Discordance With Local Guidelines for Adjuvant Chemotherapy in Breast Cancer: Reasons and Effect on Survival. Clinical Breast Cancer, 2011, 11, 46-51.	1.1	12
174	Development and validation of nomograms for predicting preterm delivery. American Journal of Obstetrics and Gynecology, 2011, 204, 242.e1-242.e8.	0.7	19
175	Interest in cavity shaving in breast conservative treatment does not depend on lumpectomy technique. Breast, 2011, 20, 358-364.	0.9	13
176	Semi-supervised model applied to the prediction of the response to preoperative chemotherapy for breast cancer. Soft Computing, 2011, 15, 1137-1144.	2.1	3
177	A double blind randomized trial of wound infiltration with ropivacaine after breast cancer surgery with axillary nodes dissection. BMC Anesthesiology, 2011, 11, 23.	0.7	30
178	Anti ancer agents for breast cancer treatment during pregnancy. Journal of Surgical Oncology, 2011, 104, 560-560.	0.8	1
179	Nonmasslike Enhancement at Breast MR Imaging: The Added Value of Mammography and US for Lesion Categorization. Radiology, 2011, 261, 69-79.	3.6	63
180	Distinct p53 Gene Signatures Are Needed to Predict Prognosis and Response to Chemotherapy in ER-Positive and ER-Negative Breast Cancers. Clinical Cancer Research, 2011, 17, 2591-2601.	3.2	52

#	Article	IF	CITATIONS
181	Characterization of Complex Adnexal Masses: Value of Adding Perfusion- and Diffusion-weighted MR Imaging to Conventional MR Imaging. Radiology, 2011, 258, 793-803.	3.6	167
182	The Usefulness of a Preoperative Compact Imager, a Hand-Held Î ³ -Camera for Breast Cancer Sentinel Node Biopsy: Final Results of a Prospective Double-Blind, Clinical Study. Journal of Nuclear Medicine, 2011, 52, 1346-1353.	2.8	26
183	Pregnancy-associated breast cancer is as chemosensitive as non-pregnancy-associated breast cancer in the neoadjuvant setting. Annals of Oncology, 2011, 22, 1582-1587.	0.6	25
184	The Molecular Subtype Classification Is a Determinant of Sentinel Node Positivity in Early Breast Carcinoma. PLoS ONE, 2011, 6, e20297.	1.1	105
185	Randomized Trial of Laparoscopically Assisted Versus Open Colorectal Resection for Endometriosis. Annals of Surgery, 2010, 251, 1018-1023.	2.1	218
186	Pathologic Response Rate After Concomitant Neo-Adjuvant Radiotherapy and Chemotherapy for Adenocarcinoma of the Uterine Cervix: A Retrospective Multicentric Study. International Journal of Gynecological Cancer, 2010, 20, 815-820.	1.2	21
187	The Google news effect: did the tainted milk scandal in China temporarily impact newborn feeding patterns in a maternity hospital?. Acta Obstetricia Et Gynecologica Scandinavica, 2010, 89, 823-827.	1.3	5
188	Laparoscopic versus laparotomic radical en bloc hysterectomy and colorectal resection for endometriosis. Surgical Endoscopy and Other Interventional Techniques, 2010, 24, 3060-3067.	1.3	27
189	Pregnancy after breast cancer: A need for global patient care, starting before adjuvant therapy. Surgical Oncology, 2010, 19, e47-e55.	0.8	16
190	Surgical resection of liver metastases from breast cancer. Surgical Oncology, 2010, 19, e79-e84.	0.8	21
191	Multiple synchronous (multifocal and multicentric) breast cancer: Clinical implications. Surgical Oncology, 2010, 19, e115-e123.	0.8	52
192	Does the use of the 2009 FIGO classification of endometrial cancer impact on indications of the sentinel node biopsy?. BMC Cancer, 2010, 10, 465.	1.1	38
193	Comparison of peritoneal carcinomatosis scoring methods in predicting resectability and prognosis in advanced ovarian cancer. American Journal of Obstetrics and Gynecology, 2010, 202, 178.e1-178.e10.	0.7	75
194	A nomogram to predict for malignant diagnosis of Blâ€RADS category 4 breast lesions. Journal of Surgical Oncology, 2010, 102, 220-224.	0.8	8
195	The role of lymph node resection in ovarian cancer: analysis of the surveillance, epidemiology, and end results (SEER) database. BJOG: an International Journal of Obstetrics and Gynaecology, 2010, 117, 1451-1458.	1.1	55
196	Prospective Comparison of Clinical and Genomic Multivariate Predictors of Response to Neoadjuvant Chemotherapy in Breast Cancer. Clinical Cancer Research, 2010, 16, 711-718.	3.2	72
197	Nomogram to Predict Subsequent Brain Metastasis in Patients With Metastatic Breast Cancer. Journal of Clinical Oncology, 2010, 28, 2032-2037.	0.8	132
198	Non-parametric kernel density estimation for the prediction of neoadjuvant chemotherapy outcomes. , 2010, 2010, 1775-8.		1

#	Article	IF	CITATIONS
199	Taxanes for breast cancer during pregnancy: a systematic review. Annals of Oncology, 2010, 21, 425-426.	0.6	141
200	Coverage and Compliance of Human Papillomavirus Vaccines in Paris: Demonstration of Low Compliance With Non-School-Based Approaches. Journal of Adolescent Health, 2010, 47, 237-241.	1.2	29
201	Breast cancer in pregnancy: Recommendations of an international consensus meeting. European Journal of Cancer, 2010, 46, 3158-3168.	1.3	238
202	Eligibility and willingness of first-year students entering university to participate in a HPV vaccination catch-up program. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2010, 148, 186-190.	0.5	24
203	Ultrastaging of lymph node in uterine cancers. Journal of Experimental and Clinical Cancer Research, 2010, 29, 5.	3.5	36
204	Wound complications after bevacizumab treatment in patients operated on for ovarian cancer. Anticancer Research, 2010, 30, 4743-7.	0.5	9
205	Evaluation of Microtubule-Associated Protein-Tau Expression As a Prognostic and Predictive Marker in the NSABP-B 28 Randomized Clinical Trial. Journal of Clinical Oncology, 2009, 27, 4287-4292.	0.8	81
206	Comparison of Models to Predict Nonsentinel Lymph Node Status in Breast Cancer Patients With Metastatic Sentinel Lymph Nodes: A Prospective Multicenter Study. Journal of Clinical Oncology, 2009, 27, 2800-2808.	0.8	231
207	Determinants of pregnancy rate in the donor oocyte model: a multivariate analysis of 450 frozen-thawed embryo transfers. Human Reproduction, 2009, 24, 3082-3089.	0.4	88
208	New Multi-Objective Algorithms for Neural Network Training Applied to Genomic Classification Data. Studies in Computational Intelligence, 2009, , 63-82.	0.7	1
209	Clues pointing to simple hysterectomy to treat early-stage cervical cancer. Oncology Reports, 2009, 22, 927-34.	1.2	14
210	Prospective Multicenter Comparison of Models to Predict Four or More Involved Axillary Lymph Nodes in Patients With Breast Cancer With One to Three Metastatic Sentinel Lymph Nodes. Journal of Clinical Oncology, 2009, 27, 5707-5712.	0.8	32
211	Neoadjuvant chemotherapy or primary surgery for stage III/IV ovarian cancer: contribution of diagnostic laparoscopy. BMC Cancer, 2009, 9, 171.	1.1	31
212	RE: External validation of a laparoscopic-based score to evaluate resectability of advanced ovarian cancers: Clues for a simplified score. Gynecologic Oncology, 2009, 112, 286.	0.6	1
213	Limits of lymphoscintigraphy for sentinel node biopsy in women with endometrial cancer. Gynecologic Oncology, 2009, 112, 348-352.	0.6	35
214	Increased fetal cell microchimerism in high grade breast carcinomas occurring during pregnancy. International Journal of Cancer, 2009, 124, 1054-1059.	2.3	50
215	Status of HER1 and HER2 in peritoneal, ovarian and colorectal endometriosis and ovarian endometrioid adenocarcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2009, 454, 525-529.	1.4	11
216	Validation of the Tenon breast cancer score for predicting non-sentinel lymph node status in breast cancer patients with sentinel lymph node metastasis: a prospective multicenter study. Breast Cancer Research and Treatment, 2009, 113, 537-543.	1.1	48

#	Article	IF	CITATIONS
217	Direct comparison of logistic regression and recursive partitioning to predict chemotherapy response of breast cancer based on clinical pathological variables. Breast Cancer Research and Treatment, 2009, 117, 325-331.	1.1	9
218	Pulmonary morbidity of diaphragmatic surgery for stage III/IV ovarian cancer. BJOG: an International Journal of Obstetrics and Gynaecology, 2009, 116, 1062-1068.	1.1	31
219	Spontaneous rectovaginal fistula during bevacizumab therapy for ovarian cancer: a case report. American Journal of Obstetrics and Gynecology, 2009, 200, e15-e16.	0.7	20
220	Diagnostic accuracy of physical examination, transvaginal sonography, rectal endoscopic sonography, and magnetic resonance imaging to diagnose deep infiltrating endometriosis. Fertility and Sterility, 2009, 92, 1825-1833.	0.5	354
221	Genital Prolapse Repair Using Porcine Skin Implant and Bilateral Sacrospinous Fixation: Midterm Functional Outcome and Quality-of-Life Assessment. Urology, 2009, 73, 245-250.	0.5	17
222	Dynamic contrastâ€enhanced magnetic resonance imaging: A useful tool for characterizing ovarian epithelial tumors. Journal of Magnetic Resonance Imaging, 2008, 28, 111-120.	1.9	150
223	Radiofrequency Thermal Ablation of Breast Cancer Local Recurrence: A Phase II Clinical Trial. Annals of Surgical Oncology, 2008, 15, 3222-3226.	0.7	24
224	Use of the Sentinel Node Procedure to Stage Endometrial Cancer. Annals of Surgical Oncology, 2008, 15, 1523-1529.	0.7	65
225	Limits of Day-Before Lymphoscintigraphy to Localize Sentinel Nodes in Women with Cervical Cancer. Annals of Surgical Oncology, 2008, 15, 2173-2179.	0.7	14
226	Development and validation of a nomogram to predict the risk of cesarean delivery in macrosomia. Acta Obstetricia Et Gynecologica Scandinavica, 2008, 87, 518-523.	1.3	12
227	Factors influencing the use and accuracy of frozen section diagnosis of epithelial ovarian tumors. American Journal of Obstetrics and Gynecology, 2008, 199, 244.e1-244.e7.	0.7	53
228	The sentinel lymph node procedure for patients with preoperative diagnosis of ductal carcinoma in situ: risk factors for unsuspected invasive disease and for metastatic sentinel lymph nodes. International Journal of Clinical Practice, 2008, 62, 1730-1735.	0.8	37
229	A suggested modification to FIGO stage III vulvar cancer. Gynecologic Oncology, 2008, 110, 83-86.	0.6	11
230	External validation of a laparoscopic-based score to evaluate resectability of advanced ovarian cancers: Clues for a simplified score. Gynecologic Oncology, 2008, 110, 354-359.	0.6	126
231	Prediction of the outcome of preoperative chemotherapy in breast cancer using DNA probes that provide information on both complete and incomplete responses. BMC Bioinformatics, 2008, 9, 149.	1.2	17
232	Sentinel lymph node biopsy in gynaecological cancers: The importance of micrometastases in cervical cancer. Surgical Oncology, 2008, 17, 227-235.	0.8	47
233	Breast cancer stroma frequently recruits fetal derived cells during pregnancy. Breast Cancer Research, 2008, 10, R14.	2.2	78
234	Transvaginal Hydrolaparoscopy: Practices in French Teaching Hospitals. Journal of Minimally Invasive Gynecology, 2008, 15, 273-276.	0.3	3

#	Article	IF	CITATIONS
235	Development of a nomogram to predict occurrence of preeclampsia. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2008, 137, 146-151.	0.5	12
236	Urinary Complications After Surgery for Posterior Deep Infiltrating Endometriosis are Related to the Extent of Dissection and to Uterosacral Ligaments Resection. Journal of Minimally Invasive Gynecology, 2008, 15, 235-240.	0.3	99
237	Chemotherapy for breast cancer during pregnancy: is epirubicin safe?. Annals of Oncology, 2008, 19, 1814-1815.	0.6	32
238	Use of the SF-36 questionnaire to predict quality-of-life improvement after laparoscopic colorectal resection for endometriosis. Human Reproduction, 2008, 23, 846-851.	0.4	80
239	Identification and Functional Analysis of a New WNT4 Gene Mutation among 28 Adolescent Girls with Primary Amenorrhea and Mul`Ilerian Duct Abnormalities: A French Collaborative Study. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 895-900.	1.8	162
240	Bayesian Classifiers for Predicting the Outcome of Breast Cancer Preoperative Chemotherapy. Lecture Notes in Computer Science, 2008, , 263-266.	1.0	1
241	Downsizing Multigenic Predictors of the Response to Preoperative Chemotherapy in Breast Cancer. Lecture Notes in Computer Science, 2008, , 157-164.	1.0	3
242	Serous and mucinous ovarian tumors express different profiles of MMP-2, -7, -9, MT1-MMP, and TIMP-1 and -2. International Journal of Oncology, 2008, 33, 1239-46.	1.4	25
243	Surgical routes and complications of hysterectomy for benign disorders: a prospective observational study in French university hospitals. Human Reproduction, 2007, 22, 260-265.	0.4	119
244	Overall Survival and Cause-Specific Mortality of Patients With Stage T1a,bN0M0 Breast Carcinoma. Journal of Clinical Oncology, 2007, 25, 4952-4960.	0.8	258
245	Outcome of laparoscopic colorectal resection for endometriosis. Current Opinion in Obstetrics and Gynecology, 2007, 19, 308-313.	0.9	91
246	Contribution of the sentinel node procedure to tailoring the radicality of hysterectomy for cervical cancer. Gynecologic Oncology, 2007, 106, 251-256.	0.6	27
247	Tattooing Breast Cancers Treated with Neoadjuvant Chemotherapy. Annals of Surgical Oncology, 2007, 14, 2233-2238.	0.7	26
248	Sentinel lymph node procedure followed by laparoscopic pelvic and paraaortic lymphadenectomy in women with IB2-II cervical cancer. Annals of Surgical Oncology, 2007, 14, 2654-2661.	0.7	18
249	Laparoscopic segmental colorectal resection for endometriosis: limits and complications. Surgical Endoscopy and Other Interventional Techniques, 2007, 21, 1572-1577.	1.3	129
250	Benign lipoblastomalike tumor of the vulva: report of a case affecting a young patient. Journal of reproductive medicine, The, 2007, 52, 223-4.	0.2	6
251	Specimen radiography as predictor of resection margin status in non-palpable breast lesions. Clinical Radiology, 2006, 61, 789-796.	0.5	39
252	Retroperitoneal Lymphangioleiomyoma Mimicking Ovarian Tumor Emerging After Tamoxifen Therapy. Obstetrics and Gynecology, 2006, 108, 762-764.	1.2	7

Roman Rouzier

#	Article	IF	CITATIONS
253	Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer. Journal of Clinical Oncology, 2006, 24, 4236-4244.	0.8	621
254	The benefit of combined maternal administration of magnesium sulfate and aminophylline. American Journal of Obstetrics and Gynecology, 2006, 194, 592-593.	0.7	0
255	Stage 1A squamous cell carcinoma of the vulva. Gynecologic Oncology, 2006, 103, 375-376.	0.6	4
256	Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer. Cancer, 2006, 107, 1459-1466.	2.0	55
257	Development and Validation of a Nomogram for Predicting Outcome of Patients With Vulvar Cancer. Obstetrics and Gynecology, 2006, 107, 672-677.	1.2	28
258	Low number of examined lymph nodes in node-negative breast cancer patients is an adverse prognostic factor. Annals of Oncology, 2006, 17, 1644-1649.	0.6	17
259	Quality of life after laparoscopic colorectal resection for endometriosis. Human Reproduction, 2006, 21, 1243-1247.	0.4	237
260	Surgery for Vulvar Cancer. Clinical Obstetrics and Gynecology, 2005, 48, 869-878.	0.6	27
261	Superficially Invasive Carcinoma of the Vulva: Diagnosis and Treatment. Clinical Obstetrics and Gynecology, 2005, 48, 862-868.	0.6	16
262	Update on the role of laparoscopy in the treatment of gynaecological malignancy. Current Opinion in Obstetrics and Gynecology, 2005, 17, 77-82.	0.9	16
263	Unusual presentation of Bartholin's gland duct cysts: anterior expansions. BJOG: an International Journal of Obstetrics and Gynaecology, 2005, 112, 1150-1152.	1.1	13
264	The natural history of breast carcinoma in patients with ≥ 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy. Cancer, 2005, 104, 229-235.	2.0	27
265	Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer, 2005, 104, 682-691.	2.0	267
266	Gene expression profiling of primary breast cancer. Current Oncology Reports, 2005, 7, 38-44.	1.8	16
267	Gene Expression Profiles in Paraffin-Embedded Core Biopsy Tissue Predict Response to Chemotherapy in Women With Locally Advanced Breast Cancer. Journal of Clinical Oncology, 2005, 23, 7265-7277.	0.8	531
268	A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding. Endocrine-Related Cancer, 2005, 12, 1059-1069.	1.6	38
269	Microtubule Associated Protein (MAP)-Tau: A Novel Mediator of Paclitaxel Sensitivity In Vitro and In Vivo. Cell Cycle, 2005, 4, 1149-1152.	1.3	74
270	Outcome After Pathologic Complete Eradication of Cytologically Proven Breast Cancer Axillary Node Metastases Following Primary Chemotherapy. Journal of Clinical Oncology, 2005, 23, 9304-9311.	0.8	366

#	Article	IF	CITATIONS
271	Factors Predictive of Distant Metastases in Patients With Breast Cancer Who Have a Pathologic Complete Response After Neoadjuvant Chemotherapy. Journal of Clinical Oncology, 2005, 23, 7098-7104.	0.8	98
272	Nomograms to Predict Pathologic Complete Response and Metastasis-Free Survival After Preoperative Chemotherapy for Breast Cancer. Journal of Clinical Oncology, 2005, 23, 8331-8339.	0.8	266
273	Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy. Clinical Cancer Research, 2005, 11, 5678-5685.	3.2	1,618
274	Microtubule-associated protein tau: A marker of paclitaxel sensitivity in breast cancer. Proceedings of the United States of America, 2005, 102, 8315-8320.	3.3	368
275	Immediate Reconstruction After Neoadjuvant Chemotherapy: Effect on Adjuvant Treatment Starting and Survival. Annals of Surgical Oncology, 2005, 12, 161-166.	0.7	69
276	Breast Cancer With Synchronous Metastases: Trends in Survival During a 14-Year Period. Journal of Clinical Oncology, 2004, 22, 3302-3308.	0.8	389
277	Malignant female adnexal tumor of probable wolffian origin relapsing after pregnancy. Gynecologic Oncology, 2004, 95, 402-404.	0.6	30
278	Expression of sigma 1 receptor in human breast cancer. Breast Cancer Research and Treatment, 2004, 87, 205-214.	1.1	65
279	Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response. Cancer, 2004, 100, 1365-1373.	2.0	143
280	Breast-conserving surgery after neoadjuvant anthracycline-based chemotherapy for large breast tumors. Cancer, 2004, 101, 918-925.	2.0	62
281	The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma. Cancer, 2004, 101, 1482-1489.	2.0	33
282	Thermal enhancement of oxaliplatin-induced inhibition of cell proliferation and cell cycle progression in human carcinoma cell lines. International Journal of Hyperthermia, 2004, 20, 405-419.	1.1	35
283	Individualized chemotherapy treatment for breast cancer: is it necessary? Is it feasible?. Drug Resistance Updates, 2004, 7, 325-331.	6.5	16
284	Inguinofemoral dissection for carcinoma of the vulva: effect of modifications of extent and technique on morbidity and survival. Journal of the American College of Surgeons, 2003, 196, 442-450.	0.2	139
285	Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. Journal of the American College of Surgeons, 2003, 197, 198-205.	0.2	245
286	Laparoscopic total pelvic exenteration for cervical cancer relapse. Gynecologic Oncology, 2003, 91, 616-618.	0.6	70
287	Laparoscopic radical hysterectomy for invasive cervical cancer: 8-year experience of a pilot study. Gynecologic Oncology, 2003, 91, 534-539.	0.6	154
288	Frozen section examination of the endocervical margin of cervical conization specimens. Gynecologic Oncology, 2003, 90, 305-309.	0.6	10

#	Article	IF	CITATIONS
289	Results of conservative management of epithelial malignant and borderline ovarian tumours. Human Reproduction Update, 2003, 9, 185-192.	5.2	77
290	Correction of uterine prolapse by the vaginal route using the uterosacral ligaments: Shirodkar procedure. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2003, 109, 214-218.	0.5	4
291	Local Relapse in Patients Treated for Squamous Cell Vulvar Carcinoma. Obstetrics and Gynecology, 2002, 100, 1159-1167.	1.2	13
292	Local relapse in patients treated for squamous cell vulvar carcinoma Incidence and prognostic value. Obstetrics and Gynecology, 2002, 100, 1159-1167.	1.2	101
293	Incidence and Prognostic Significance of Complete Axillary Downstaging After Primary Chemotherapy in Breast Cancer Patients With T1 to T3 Tumors and Cytologically Proven Axillary Metastatic Lymph Nodes. Journal of Clinical Oncology, 2002, 20, 1304-1310.	0.8	272
294	Perineoplasty for the treatment of introital stenosis related to vulvar lichen sclerosus. American Journal of Obstetrics and Gynecology, 2002, 186, 49-52.	0.7	79
295	Primary adenocarcinoma of the rectovaginal septum: a case report and literature review. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2001, 95, 111-113.	0.5	19
296	Primary Chemotherapy for Operable Breast Cancer: Incidence and Prognostic Significance of Ipsilateral Breast Tumor Recurrence After Breast-Conserving Surgery. Journal of Clinical Oncology, 2001, 19, 3828-3835.	0.8	141
297	Immunocytochemical detection of bone marrow micrometastases in colorectal carcinoma patients, using a monoclonal antibody to villin. Cytometry, 2001, 46, 281-289.	1.8	2
298	Prognostic Significance of Epithelial Disorders Adjacent to Invasive Vulvar Carcinomas. Gynecologic Oncology, 2001, 81, 414-419.	0.6	65
299	The subtleties of intestinal metaplasia. Gut, 2001, 49, 8-8.	6.1	2
300	Hypertrophy of labia minora: Experience with 163 reductions. American Journal of Obstetrics and Gynecology, 2000, 182, 35-40.	0.7	280